Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Biomarkers for Neurodegenerative Disorders: From Bench to Bedside
share announcement

Biomarkers for Neurodegenerative Disorders: From Bench to Bedside

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".

Deadline for manuscript submissions: 30 April 2025 | Viewed by 766

Special Issue Editor

Dr. George P. Paraskevas

E-Mail Website
Guest Editor
2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Interests: cognitive disorders; movement disorders; Alzheimer’s disease; frontotemporal dementia; dementia with Lewy bodies; Parkinson’s disease; tauopathies; synucleinopathies

Special Issue Information

Dear Colleagues,

Our knowledge on neurodegenerative disorders is rapidly expanding. Molecular, neuropsychological and imaging markers are valuable tools for understanding the various mechanisms underlying these disorders. In addition, such biomarkers may be of clinical value, and some of them have been incorporated in diagnostic criteria and guidelines for neurodegenerative disorders, including Alzheimer’s disease. This Special Issue provides insights into the use of biomarkers in neurodegenerative disorders, including (but not limited to) Alzheimer’s disease, frontotemporal dementias, Lewy body dementia, Parkinson’s disease, atypical parkinsonian disorders and amyotrophic lateral sclerosis. Among others, fluid biomarkers (cerebrospinal fluid or blood), structural imaging biomarkers (atrophy), positron emission tomography (PET) biomarkers (amyloid- and/or tau-PET and others), neuropsychological testing and genetic biomarkers are especially important. Original research, review and case report papers are all acceptable. Papers on biomarkers related to basic mechanisms are welcome, but the main interest is on clinically meaningful biomarkers, their help in the (differential) diagnosis of patients with cognitive and movement disorders, and in selecting patients for newer or emerging treatments.

Dr. George P. Paraskevas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dementia
  • Alzheimer’s disease
  • frontotemporal dementia
  • dementia with Lewy bodies
  • parkinsonism
  • tau protein
  • TDP-43
  • α-synuclein
  • Tau-PET
  • amyloid-PET

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 1681 KiB  
Article
Cerebrospinal Fluid Classical Biomarker Levels in Mixed vs. Pure A+T+ (A+T1+) Alzheimer’s Disease
by Ioanna Tsantzali, Athanasia Athanasaki, Fotini Boufidou, Vasilios C. Constantinides, Maria-Ioanna Stefanou, Christos Moschovos, Christina Zompola, Sotirios G. Paraskevas, Anastasios Bonakis, Sotirios Giannopoulos, Georgios Tsivgoulis, Elisabeth Kapaki and George P. Paraskevas
Biomedicines 2024, 12(12), 2904; https://doi.org/10.3390/biomedicines12122904 - 20 Dec 2024
Viewed by 512
Abstract
Background: Alzheimer’s disease (AD) may present with pure (typical or atypical) and mixed phenotypes, sometimes causing difficulties in (differential) diagnosis. In order to achieve a diagnostic accuracy as high as possible, the diagnosis of AD during life depends on various biomarkers, including [...] Read more.
Background: Alzheimer’s disease (AD) may present with pure (typical or atypical) and mixed phenotypes, sometimes causing difficulties in (differential) diagnosis. In order to achieve a diagnostic accuracy as high as possible, the diagnosis of AD during life depends on various biomarkers, including the cerebrospinal fluid (CSF) biomarkers. Methods: Classical CSF AD biomarkers were determined in a total of 61 patients, classified as both beta amyloid- and tau-positive A+T+ (or A+T1+ according to the recently revised Alzheimer Association criteria for diagnosis and staging of AD). Twenty one of these patients fulfilled the criteria for mixed AD (mixed with Lewy bodies, cerebrovascular disease, or normal pressure hydrocephalus), whilst 40 had pure AD. Results: Patients did not differ with respect to gender, education, disease duration, and cognitive status. After controlling for confounding factors, no difference was observed between mixed and pure AD groups in Aβ42 or Aβ42/Aβ40 levels. Although by definition, patients of both groups had abnormal (increased) levels of phospho-tau181, the mixed AD group presented with lower (less abnormal) levels of phospho-tau181 and total tau as compared to the pure group. Conclusions: In patients with AD of comparable cognitive status, mixed AD cases may present with lower levels of tau proteins and, if close to the cut-off values, diagnostic uncertainty may be increased. Full article
(This article belongs to the Special Issue Biomarkers for Neurodegenerative Disorders: From Bench to Bedside)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop